CLINICAL OUTCOMES OF VANCOMYCIN THERAPEUTIC MONITORING SERVICES AT MINISTRY OF HEALTH HOSPITAL IN SAUDI ARABIA

Author(s)

Alomi YA1, Almudaiheem HY2
1Ministry of Health, RIYADH, Saudi Arabia, 2Ministry of Health, Riyadh, Saudi Arabia

OBJECTIVES:  To explore the clinical outcome of Vancomycin therapeutic monitoring services at Ministry of Health Hospital in Saudi Arabia METHODS:  It is a cross-sectional clinical outcome of Vancomycin therapeutic monitoring over a period of 9-months at King Saud Medical City (KSMC). The study divided into three phases, each of 3-month duration for data collection and evaluation. The first phase (Phase I) was the Pre-intervention phase; the second was the intervention phase (phase II), the third phase Post-intervention phase (Phase III) without any pharmacist. Any patient received Vancomycin followed up by trained pharmacist. The pharmacist followed a labeled indication, all pharmacokinetics parameters such as weight, height, bug culture sensitivity, and any adjustments in dosage, drug level and duration of administration recorded on a therapeutic drug monitoring form on a regular basis at each phase. RESULTS:  The total number of patients 53 in phase I, 22 in phase II, and 31 in phase III respectively. The labeled indication adherences increased significantly from phase I to phase II 24 (45.3%) to 19 (86.4%) respectively while significantly decreased in 21 (67.7%) patients in phase III (p<0.05). The non-labeled indications adherences decreased from phase I to phase II 29 (54.7 %) to 3 (13.6%) patients respectively. The levels of Vancomycin as sub-therapeutic level significantly decreased from 23 (43.4%) to 0 (0.0%)in patients (p<0.5), the therapeutic Vancomycin level significantly increased from 11 (20.8%) to 20 (90.9% ) in patients (p<0.05). The wrong sampling time significantly decreased from 22 (41.5%) to 7 (31.8%) in patients (p<0.05). CONCLUSIONS:  There is a significant adherence to Vancomycin therapeutic guidelines. Targeting to expanding the role of the pharmacist in Vancomycin therapeutic monitoring is required to improve patient outcome and prevent Vancomycin drug-related problems, and avoid the unnecessary additional cost.

Conference/Value in Health Info

2017-05, ISPOR 2017, Boston, MA, USA

Value in Health, Vol. 20, No. 5 (May 2017)

Code

PHP152

Topic

Epidemiology & Public Health

Topic Subcategory

Safety & Pharmacoepidemiology

Disease

Multiple Diseases

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×